<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015794</url>
  </required_header>
  <id_info>
    <org_study_id>404/09</org_study_id>
    <nct_id>NCT01015794</nct_id>
  </id_info>
  <brief_title>Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation</brief_title>
  <official_title>Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators aim to quantitate the extent of cervical and upper thoracic&#xD;
      brown adipose tissue (BAT) activation in lean and obese humans via positron emission&#xD;
      tomography-computed tomography (PET-CT) in response to the non-specific beta adrenergic&#xD;
      receptor (AR) agonist ephedrine. The investigators hypothesise that this pharmacological&#xD;
      adrenergic stimulus will result in activation of BAT in these participants, and that this&#xD;
      activation will be reduced in obese patients. This study will provide important preliminary&#xD;
      information with respect to allowing the investigators to progress with longer trials with&#xD;
      specific beta 3 AR agonists.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BAT activity via PET-CT</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Adrenergic agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ephedrine hydrochloride</intervention_name>
    <description>single oral dose, 1mg/kg body weight</description>
    <arm_group_label>Adrenergic agonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ephedrine hydrochloride</intervention_name>
    <description>single dose of 1 mg/kg body weight</description>
    <arm_group_label>Adrenergic agonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: healthy group&#xD;
&#xD;
          -  Males aged 20 - 40 years&#xD;
&#xD;
          -  Free of overt coronary disease (on history, medical examination and ECG)&#xD;
&#xD;
          -  Fasting plasma glucose &lt; 6.1 mmol/L and 2 hour OGTT glucose &lt; 7.8 mmol/L&#xD;
&#xD;
          -  Unmedicated&#xD;
&#xD;
          -  No major illness&#xD;
&#xD;
          -  BMI 18 - 25&#xD;
&#xD;
        Inclusion Criteria: obese group&#xD;
&#xD;
          -  Males aged 20 - 40 years&#xD;
&#xD;
          -  Free of overt coronary disease (on history, medical examination and ECG)&#xD;
&#xD;
          -  Unmedicated&#xD;
&#xD;
          -  No major illness&#xD;
&#xD;
          -  BMI 30+&#xD;
&#xD;
          -  Weight &lt; 100 kg&#xD;
&#xD;
          -  Height &lt; 185 cm&#xD;
&#xD;
        The inclusion criteria (Obese participants) of body weight less than ~100 kg is implemented&#xD;
        as the PET-CT scanner to be utilised (protocol described subsequently) has a limited&#xD;
        patient volume. Therefore to fit within the criteria of BMI &gt; 30, only patients of height&#xD;
        ~183 cm or less can be recruited, and inclusion of borderline participants will be&#xD;
        discussed with co-investigators from the Alfred Hospital Nuclear Medicine Department.&#xD;
&#xD;
        Exclusion Criteria: healthy group&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
        Exclusion Criteria: obese group&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Participant in research projects involving ionising radiation within the past 5 years&#xD;
&#xD;
          -  claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alfred Hospital Heart Centre</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <results_reference>
    <citation>Carey AL, Formosa MF, Van Every B, Bertovic D, Eikelis N, Lambert GW, Kalff V, Duffy SJ, Cherk MH, Kingwell BA. Ephedrine activates brown adipose tissue in lean but not obese humans. Diabetologia. 2013 Jan;56(1):147-55. doi: 10.1007/s00125-012-2748-1. Epub 2012 Oct 13.</citation>
    <PMID>23064293</PMID>
  </results_reference>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

